Strategy Portfolio & Performance, AstraZeneca, Wilmington, Delaware, USA.
Clin Pharmacol Ther. 2013 Sep;94(3):359-66. doi: 10.1038/clpt.2013.91. Epub 2013 May 8.
2012 was a robust year for new molecular entity (NME) approvals in the major geographic regions. What is behind this apparent improved performance? Has the pharmaceutical industry turned the tide in research and development productivity? In this analysis, we look not only at the number of approvals in 2012 but also at their clinical and market potential. We discuss how changes in the regulatory and reimbursement environment impact current industry performance and how this might evolve.
2012 年是各大主要地区新药（NME）批准的丰硕之年。这种明显的改善背后的原因是什么？制药行业是否在研发生产力方面扭转了局面？在这项分析中，我们不仅着眼于 2012 年的批准数量，还着眼于它们的临床和市场潜力。我们讨论了监管和报销环境的变化如何影响当前行业的表现，以及这种情况可能会如何演变。
